Unique ID issued by UMIN | UMIN000007441 |
---|---|
Receipt number | R000008771 |
Scientific Title | Pilot study of nutritional intervention by elemental diet for lung cancer during chemotherapy |
Date of disclosure of the study information | 2012/03/06 |
Last modified on | 2015/03/07 00:29:22 |
Pilot study of nutritional intervention by elemental diet for lung cancer during chemotherapy
Pilot study of nutritional intervention for lung cancer during chemotherapy
Pilot study of nutritional intervention by elemental diet for lung cancer during chemotherapy
Pilot study of nutritional intervention for lung cancer during chemotherapy
Japan |
Lung cancer
Pneumology |
Malignancy
NO
To assess the efficacy of nutritional intervention by elemental diet (Elental) in patieints with chemotherapy for non-small cell lung cancer and small cell lung cancer.
Efficacy
Exploratory
Pragmatic
Phase I
Decrease ratio of body weight
Alb, Pre-Alb, Transfferin, QOL, Side effects, Overall survival, Progression free survival, one year survival rate, chemotherapeutical drug, Chemotherapeutical drug compliance
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
We performed nutritional intervention by elemental diet (Elental) in patieints with non-small cell lung cancer and small-cell lung cancer for 16 weeks from first day of the initial chemotherapy.
20 | years-old | <= |
Not applicable |
Male and Female
"1)Histologically proven non-squamous non-small cell lung cancer
2)Patient who has measurable lesion by RECIST
3-1)Non-small cell lung cancer: Stage 3B/4 NSCLC
3-2)Small cell lung cancer: extensive small-cell lung cancer
4)ECOG performance status: 0-1
5)Aged>=20 years
6)No chemotherapy, radiotherapy, immunotherapy as prior therapy as for NSCLC
7)Adequate organ functions
WBC>= 4000/mm3 & <= 12000mm3
Neutro>=2000/mm3
Platelet >= 100000/mm3
Hemoglobin>= 9.5g/dL
GOTand GPT< 2.5*the upper limit of normal
Bilirubin<= 2.0mg/dL
Serum creatinine<= 1.2mg/dL or 24hr creatinine clearance> 60mL/min
PaO2>= 60Torr
8)Life expectancy >= 4months
9)Written informed consent"
"
1)Severe infections
2)Fever of over 38 degrees
3)Serious complications such as cardiac disease, interstitial pneumonia, bleeding diathesis, uncontrollable hypertension or diabetes mellitus
4)History of active double cancer within 5 years
5)Symptomatic brain metastases
6)Pleural effusion or ascites to treat
7)Pericardial effusion
8)Cchickenpox
9)Motor weakness or disorder of peripheral nerve
10)History of drug hypersensitivity
11)Pregnancy
12)History of hypersensitivity against elements of Elental
13)Severe diabetes, and patients suspected abnormal sugar metabolism because of high dosage of steroids
14)Abnormal amino acid metabolism
15)Inappropriate judged by physicians"
20
1st name | |
Middle name | |
Last name | Kazutoshi Isobe |
Toho University Omori Medical Center
Department of Respiratory Medicine
6-11-1 Omori-Nishi, Ota-ku Tokyo Japan
03-3762-4151
kazutoshiisobe@aol.com
1st name | |
Middle name | |
Last name | Kazutoshi Isobe |
Toho University Omori Medical Center
Department of Respiratory Medicine
6-11-1 Omori-Nishi, Ota-ku Tokyo Japan
03-3762-4151
kazutoshiisobe@aol.com
Toho University
None
Self funding
NO
2012 | Year | 03 | Month | 06 | Day |
Unpublished
Open public recruiting
2011 | Year | 02 | Month | 01 | Day |
2011 | Year | 02 | Month | 01 | Day |
2012 | Year | 03 | Month | 05 | Day |
2015 | Year | 03 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008771